IIL
REGN icon

Income Insurance Ltd’s Regeneron Pharmaceuticals REGN Stock Holding History

Income Insurance Ltd’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-312
Closed -$241K – 189
2026
Q1 		$241K Hold
312
– – 0.16% 130
2025
Q4 		$241K Buy
+312
New +$212K 0.16% 130

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Income Insurance Ltd's REGN Position: Q2 2026 in Review

Income Insurance Ltd sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 312 shares — an estimated $241K sold.

Income Insurance Ltd first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $241K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Income Insurance Ltd reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Income Insurance Ltd sold 312 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $241K.
  • Income Insurance Ltd first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Income Insurance Ltd's Regeneron Pharmaceuticals position peaked at $241K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Income Insurance Ltd's 13F filing for Q2 2026, filed 24 Jul 2026.